Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Mole101on Apr 02, 2021 10:49pm
125 Views
Post# 32933160

RE:RE:RE:RE:RE:RE:RE:RE:Tohru Hasegawa

RE:RE:RE:RE:RE:RE:RE:RE:Tohru Hasegawa

I listen to the comments from few who watch the interview and nothing much out of what we got in the NR . Is it smart for the CEO to do that ? I guess by the response of some here, it wasn't. Does it rise to the level of lawyering up and chase the CEO  and VP? Well , it's your money either invested or out of pocket . We should get update in the next couple of weeks and direction with respect to FDA 

quote=Laliberte2020]
Yes I am aware of all those interviews. In the past year, everytime Algernon got any tiny bit of nr, we saw CM on proactive, biopub , fb live, etc...On that same day. Now we had the most awaited event of the last year for this company, and we get a half page nr with missing details, then complete silence, but now he gave complementary information to some paid subscribers... I am sure some shareholders got influenced into selling with the sharp sp drop of the last trading days. I am just saying, if CM had something to say, just make it public.[/quote]
 

<< Previous
Bullboard Posts
Next >>